Form 4: 10x Genomics Director Sarah Teichmann Reports Acquisition of Restricted Stock Units

10x Genomics, Inc. Director Sarah A. Teichmann reported the acquisition of 15,357 restricted stock units (RSUs) on June 3, 2025, increasing her beneficial ownership to 34,359 shares.

Summary

• Director Sarah A. Teichmann of 10x Genomics, Inc. (TXG) acquired 15,357 shares of Class A Common Stock.
• The transaction occurred on June 3, 2025, and was reported via a Form 4 filing on June 5, 2025.
• These shares are Restricted Stock Units (RSUs), granted at a price of $0, representing a contingent right to receive one share of Class A Common Stock upon vesting.
• The RSUs are scheduled to vest in quarterly installments, with 1/4th vesting on each quarterly anniversary measured from May 21, 2025, contingent on Ms. Teichmann's continued service as a director.
• Following this acquisition, Ms. Teichmann's total beneficial ownership of Class A Common Stock stands at 34,359 shares.

Sentiment

Score: 7

Explanation: The grant of Restricted Stock Units to a director is a positive event as it aligns the director's interests with long-term shareholder value, indicating continued commitment to the company. It is a routine compensation event and does not reflect on the company's operational performance or financial health directly, hence a moderately positive sentiment.

Positives

• The grant of Restricted Stock Units (RSUs) to Director Sarah A. Teichmann aligns her interests with those of long-term shareholders, as the value of her compensation is tied to the company's stock performance.
• Equity compensation for directors is a standard practice that encourages commitment and strategic oversight.

Future Outlook

The vesting schedule for the acquired Restricted Stock Units indicates that 1/4th of the RSUs will vest on each quarterly anniversary measured from May 21, 2025, contingent on the director's continued service.

Industry Context

This Form 4 filing details a routine equity compensation event for a director, which is a common practice across publicly traded companies in the biotechnology and life sciences tools industry. Such grants are designed to align the interests of company leadership with shareholder value creation.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) as a form of director compensation is a widely adopted practice across industries, including the biotechnology and life sciences sector where 10x Genomics operates.
• This method of compensation is consistent with global benchmarks for corporate governance, as it ties a portion of director remuneration directly to the company's stock performance, similar to practices at peer companies like Illumina (ILMN) or Pacific Biosciences of California (PACB) which also utilize equity grants for their board members.
• The specific number of RSUs granted (15,357) would typically be determined by the company's compensation committee based on factors such as the director's role, tenure, and overall compensation philosophy relative to its competitive landscape, though this document does not provide comparative figures.

Related Party Transactions

• The acquisition of Restricted Stock Units by Sarah A. Teichmann, a director of 10x Genomics, Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with shareholder value creation, potentially leading to more focused long-term decision-making.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The RSUs will vest in quarterly installments, with 1/4th vesting on each quarterly anniversary measured from May 21, 2025, subject to the Reporting Person continuing as a service provider.

Key Dates

Recommendation

Keywords

10x Genomics, TXG, Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Beneficial Ownership